Core Insights - Mural Oncology has decided not to progress the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with KEYTRUDA® for platinum-resistant ovarian cancer due to lack of statistically significant improvement in overall survival compared to chemotherapy [1][6] - The median overall survival was reported as 10.1 months for the combination therapy versus 9.8 months for chemotherapy, with a hazard ratio of 0.98 indicating no significant benefit [1] - The company remains focused on its upcoming topline results from the ARTISTRY-6 trial in mucosal melanoma, expected in Q2 2025 [2][4] Company Overview - Mural Oncology is a clinical-stage immuno-oncology company developing cytokine-based immunotherapies, with a focus on leveraging its protein engineering platform [9] - The lead candidate, nemvaleukin, is designed to enhance antitumor effects while minimizing toxicities associated with traditional IL-2 therapies [7] - The company has treated over 800 patients across its broader clinical program, demonstrating a favorable safety profile for nemvaleukin [3][9] Clinical Trials - The ARTISTRY-7 trial involved 456 patients and was designed to compare nemvaleukin with pembrolizumab against investigator's choice chemotherapy, focusing on overall survival as the primary endpoint [6] - The ARTISTRY-6 trial is currently evaluating nemvaleukin in mucosal melanoma, with topline data readouts expected in Q2 2025, alongside preliminary data for cutaneous melanoma in the same timeframe [4][8]
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer